Medical device giant Boston Scientific touts very low rates of paravalvular leakage in 30-day results from its Lotus transcatheter aortic valve implantation study.
Massachusetts-based medical device titan Boston Scientific (NYSE:BSX) released early data from a study of its Lotus transcatheter aortic valve implantation system, highlighting very low rates of paravalvular leakage that analysts said could give the company some leverage in the highly charged TAVI market.
U.K. researchers report that Medtronic's CoreValve transcatheter aortic valve implantation system is a cost-effective alternative to medical management, with low mortality and strokes rates and overall improvement in quality of life.
The latest update from Medtronic's (NYSE:MDT) ADVANCE registry of patients treated with the CoreValve transcatheter aortic valve implantation evaluated the technology from a cost perspective, with researchers reporting that CoreValve is worth the money for patients with severe aortic stenosis.
Medical device giant Medtronic unveils a 1st look from its global Symplicity renal denervation registry and says its Symplicity Spyral multi-electrode catheter can cut procedure times in half.
Medical device industry giant Medtronic (NYSE:MDT) this week offered a 1st look at results from its global Symplicity registry of renal denervation patients, finding that treatment with the company's Symplicity system appears safe as well as effective in real-world patients.